Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 21, 2025

Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, William Wierda, MD

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.

Episodes in this series

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 8 Navigating CLL Treatment Choices

EP. 8 Navigating CLL Treatment Choices

EP. 9 Therapy Sequencing in CLL

EP. 9 Therapy Sequencing in CLL

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 11 MCL Therapy Selection and Sequencing

EP. 11 MCL Therapy Selection and Sequencing

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 25 Payer Policies and Access Strategies

EP. 25 Payer Policies and Access Strategies

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Navigating Treatment Sequencing and Defining Failure in Moderate-to-Severe Atopic Dermatitis

ByAngela J. Lamb, MD

July 17th 2026

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

ByNadege Gunn, MD

July 17th 2026

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Trending on AJMC

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Active US Drug Shortages Rise for Third Straight Quarter

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD